L
Leo Luznik
Researcher at Johns Hopkins University
Publications - 234
Citations - 12318
Leo Luznik is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Transplantation & Graft-versus-host disease. The author has an hindex of 52, co-authored 212 publications receiving 9781 citations. Previous affiliations of Leo Luznik include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
Leo Luznik,Paul O'Donnell,Paul O'Donnell,Heather J. Symons,Allen R. Chen,M. Susan Leffell,Marianna Zahurak,Ted Gooley,Ted Gooley,S Piantadosi,Michele Kaup,Richard F. Ambinder,Carol Ann Huff,William Matsui,Javier Bolaños-Meade,Ivan Borrello,Jonathan D. Powell,Elizabeth Harrington,Sandy Warnock,Mary E.D. Flowers,Mary E.D. Flowers,Robert A. Brodsky,Brenda M. Sandmaier,Brenda M. Sandmaier,Rainer Storb,Rainer Storb,Richard J. Jones,Ephraim J. Fuchs +27 more
TL;DR: Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD, and there was a trend toward a lower risk of extensive chronic GVHD (cGVHD) among recipients of 2 versus 1 dose of posttrans transplantation Cy.
Journal ArticleDOI
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
Stefan O. Ciurea,Mei-Jie Zhang,Andrea Bacigalupo,Asad Bashey,Frederick R. Appelbaum,Omar S. Aljitawi,Philippe Armand,Joseph H. Antin,Junfang Chen,Steven M. Devine,Daniel H. Fowler,Leo Luznik,Ryotaro Nakamura,Paul O'Donnell,Miguel-Angel Perales,Sai Ravi Pingali,David L. Porter,Marcie L. Riches,Olle Ringdén,Vanderson Rocha,Ravi Vij,Daniel J. Weisdorf,Richard E. Champlin,Mary M. Horowitz,Ephraim J. Fuchs,Mary Eapen +25 more
TL;DR: It is suggested that survival for patients with AML after haploidentical transplantation with posttransplant cyclophosphamide is comparable with matched unrelated donor transplantation.
Journal ArticleDOI
HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease.
Javier Bolaños-Meade,Ephraim J. Fuchs,Leo Luznik,Sophie Lanzkron,Christopher Gamper,Richard J. Jones,Robert A. Brodsky +6 more
TL;DR: Nonmyeloablative conditioning with posttransplantation high-dose cyclophosphamide expands the donor pool, making marrow transplantation feasible for most patients with sickle cell disease, and is associated with a low risk of complications, even with haploidentical related donors.
Journal ArticleDOI
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.
Leo Luznik,Javier Bolaños-Meade,Marianna Zahurak,Allen R. Chen,B. Douglas Smith,Robert A. Brodsky,Carol Ann Huff,Ivan Borrello,William Matsui,Jonathan D. Powell,Yvette L. Kasamon,Steven N. Goodman,Allan D. Hess,Hyam I. Levitsky,Richard F. Ambinder,Richard J. Jones,Ephraim J. Fuchs +16 more
TL;DR: High-dose posttransplantation cyclophosphamide is an effective single-agent prophylaxis of acute and chronic GVHD after BuCy conditioning and HLA-matched BMT (clinicaltrials.gov no. NCT00134017).
Journal ArticleDOI
Durable engraftment of major histocompatibility complex–incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide
TL;DR: Results indicate that stable engraftment of MHC-incompatible cells can be induced after fludarabine-based, nonmyeloablative conditioning and that it serves as a platform for adoptive immunotherapy with donor lymphocyte infusions.